Landos Biopharma Q3 EPS $(0.94) Misses $(0.88) Estimate
Portfolio Pulse from Benzinga Newsdesk
Landos Biopharma reported Q3 losses of $(0.94) per share, missing the analyst consensus estimate of $(0.88) by 6.82 percent. This is a 53 percent increase over losses of $(2.00) per share from the same period last year.
November 09, 2023 | 1:27 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Landos Biopharma's Q3 earnings missed analyst estimates, which could negatively impact the stock in the short term.
Landos Biopharma's Q3 earnings missed analyst estimates by 6.82%, which is typically seen as a negative signal by investors and could lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100